During the recent session, Plus Therapeutics Inc (NASDAQ:PSTV)’s traded shares were 11.82 million, with the beta value of the company hitting 0.44. At the last check today, the stock’s price was $1.60, reflecting an intraday gain of 8.50% or $0.13. The 52-week high for the PSTV share is $2.67, that puts it down -66.87 from that peak though still a striking 85.0% gain since the share price plummeted to a 52-week low of $0.24. The company’s market capitalization is $18.79M, and the average intraday trading volume over the past 10 days was 44.58 million shares, and the average trade volume was 15.84 million shares over the past three months.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
Plus Therapeutics Inc (PSTV) registered a 8.50% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.50% in intraday trading to $1.60, hitting a weekly high. The stock’s 5-day price performance is 15.58%, and it has moved by 109.87% in 30 days. Based on these gigs, the overall price performance for the year is -16.93%. The short interest in Plus Therapeutics Inc (NASDAQ:PSTV) is 0.93 million shares and it means that shorts have 0.04 day(s) to cover.
Plus Therapeutics Inc (PSTV) estimates and forecasts
In the rating firms’ projections, revenue will increase 12.52% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.01M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 1.38M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.31M and 1.68M respectively. In this case, analysts expect current quarter sales to shrink by -23.33% and then drop by -17.51% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 68.20%. While earnings are projected to return 56.01% in 2025, the next five years will return 33.56% per annum.
PSTV Dividends
Plus Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Plus Therapeutics Inc insiders own 17.36% of total outstanding shares while institutional holders control 11.50%, with the float percentage being 13.92%.
Also, the Mutual Funds coming in first place with the largest holdings of Plus Therapeutics Inc (PSTV) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 34.96 shares. This amounts to just over 0.30 percent of the company’s overall shares, with a $51734.0 market value. The same data shows that the other fund manager holds slightly less at 32.54, or about 0.28% of the stock, which is worth about $48160.0.
